<DOC>
	<DOCNO>NCT01769755</DOCNO>
	<brief_summary>To assess safety efficacy intravenous ( IV ) PDA001 infuse every two week 5 total infusion subject Crohn 's disease refractory one standard Crohn 's disease therapy .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Dose-Escalation Study Determine Safety Efficacy Intravenous Infusion Human Placenta-Derived Cells ( PDA001 ) Treatment Crohn 's Disease</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , dose-escalation study study 3 cohort subject Crohn 's Disease include ( limited ) colonic involvement . Each cohort ( n = 9 ) include PDA001 treated subject ( n = 6 ) well placebo ( vehicle control ) treat subject ( n = 3 ) . Cohorts enrol sequentially , begin low dose cohort ( 1/4 unit PDA001 ) progress maximum tolerate dose IV PDA001 determine .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>• Males females 18 75 year age time sign informed consent document . Minimum weight subject 40 kg screening . Subject must inflammatory Crohn 's Disease ( CD ) diagnose least 6 month great 15 year prior treatment Investigational Product ( IP ) . Subject must confirmation ongoing CD ileocolonoscopy screening . Subject must Crohn 's Disease Activity Index ( CDAI ) score ≥ 220 ≤ 450 assess Visit 1 Visit 2 . Subject significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study include limited Liver Function Tests Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal screening . Serum creatinine concentration &gt; 2.0 mg/dl screening . Alkaline phosphatase &gt; 2.5 x upper limit normal screening . Bilirubin level &gt; 2 mg/dL ( unless subject know Gilbert 's disease ) . Pregnant lactating female . Morbidly obese subject Body Mass Index ( BMI ) &gt; 35 screening ) . Subject untreated chronic infection include Clostridium difficile toxin positive screening treatment infection antibiotic within 4 week prior dose IP ( treat urinary tract infection drain perianal abscess ) . Note : Stable dos antibiotic use treat Crohn 's Disease allow . Subject organic heart disease ( eg , congestive heart failure ) , clinically significant arrhythmia clinically significant abnormal finding Electrocardiograms ( ECG ) . Subject history malignancy within 5 year ( except basal cell carcinoma skin surgically cure , remote history cancer consider cure positive Pap smear subsequent negative follow ) . Subject stricture bowel require hospitalization within 182 day prior treatment IP . Subject bowel surgery perianal ( example , fistulotomy , seton placement , abscess drainage ) previous abscess drainage within 182 day prior treatment IP . Subject surgery within 28 day prior treatment IP . Subject colostomy , ileostomy ileal pouch anal anastomosis . Subject receive investigational agent —an agent device approve FDA market use indication—within 90 day ( 5 halflives , whichever long ) prior treatment investigational product . Subject receive previous cell therapy . Subject expect elective surgery time Visit 1 ( screen ) Visit 7 ( end induction phase ) . Subject concurrent diagnosis ulcerative colitis . Subjects protein C S deficiency . Subjects prior history thrombophlebitis pathological arterial venous thrombosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>Fistula</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Colon</keyword>
	<keyword>Stem cell</keyword>
</DOC>